- •NOACs effectiveness/safety has been described according to dose in a large AF cohort.
- •NOACs high dose decreased the risk of all-cause death.
- •NOACs high and low dose decreased the risk of intracranial bleeding.
- •NOACs low dose increased the rate of major bleeding.
- •Evaluation of the patients’ characteristic is pivotal choosing the proper NOACs dose.
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to European Journal of Internal Medicine
- Stroke prevention, evaluation of bleeding risk, and anticoagulant treatment management in atrial fibrillation contemporary international guidelines.Can J Cardiol. 2019; 35: 619-633https://doi.org/10.1016/j.cjca.2019.02.009
- Contemporary stroke prevention strategies in 11 096 European patients with atrial fibrillation: a report from the EURObservational research programme on atrial fibrillation (EORP-AF) long-term general registry.Europace. 2018; 20: 747-757https://doi.org/10.1093/europace/eux301
- Inappropriate doses of direct oral anticoagulants in real-world clinical practice: prevalence and associated factors. A subanalysis of the FANTASIIA registry.Europace. 2018; 20: 1577-1583https://doi.org/10.1093/europace/eux316
- Effectiveness and safety of off-label dose-reduced direct oral anticoagulants in atrial fibrillation.Am J Med. 2019; 132: 847-855https://doi.org/10.1016/j.amjmed.2019.01.025
- Pattern and impact of off-label underdosing of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation who are indicated for standard dosing.Am J Cardiol. 2020; 125: 1332-1338https://doi.org/10.1016/j.amjcard.2020.01.044
- Frequency and outcomes of reduced dose non-vitamin K antagonist anticoagulants: results from ORBIT-AF II (The outcomes registry for better informed treatment of atrial fibrillation II).J Am Heart Assoc. 2018; 7https://doi.org/10.1161/JAHA.117.007633
- The 2018 European heart rhythm association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation.Eur Heart J. 2018; 39: 1330-1393https://doi.org/10.1093/eurheartj/ehy136
- Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.BMJ. 2017; 356: j510https://doi.org/10.1136/bmj.j510
- Efficacy and safety of reduced-dose non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a meta-analysis of randomized controlled trials.Eur Heart J. 2019; 40: 1492-1500https://doi.org/10.1093/eurheartj/ehy802
- Cessation of oral anticoagulation is an important risk factor for stroke and mortality in atrial fibrillation patients.Thromb Haemost. 2017; 117https://doi.org/10.1160/TH16-12-0961
- Association between antithrombotic treatment and outcomes at 1-year follow-up in patients with atrial fibrillation: the EORP-AF general long-term registry.Europace. 2019; 21: 1013-1022https://doi.org/10.1093/europace/euz032
- A 10 year study of hospitalized atrial fibrillation-related stroke in England and its association with uptake of oral anticoagulation.Eur Heart J. 2018; 39: 2975-2983https://doi.org/10.1093/eurheartj/ehy411
- Global, regional, and national prevalence, incidence, mortality, and risk factors for atrial fibrillation, 1990–2017: results from the global burden of disease study 2017.Eur Hear J - Qual Care Clin Outcomes. 2020; https://doi.org/10.1093/ehjqcco/qcaa061
- Causes of death in anticoagulated patients with atrial fibrillation.J Am Coll Cardiol. 2016; 68: 2508-2521https://doi.org/10.1016/j.jacc.2016.09.944
- Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials.Lancet. 2014; 383: 955-962https://doi.org/10.1016/S0140-6736(13)62343-0